Kantar Health and Synix to Host Seminar That Will Aid in Understanding the Healthcare Systems and Relationships with Stakeholders in the U.S. and Europe to Build a Market Access Strategy
NEW YORK, October 28, 2013—Kantar Health, a leading global healthcare consulting firm, and Synix will host a seminar, “The Keys to Market Access Success in the U.S. and European Markets,” on November 14 in Tokyo.
Changes in the healthcare system in the U.S. and Europe have a significant impact on the process of introducing new pharmaceutical agents, particularly high-cost specialty drugs such as oncolytics, to these markets. The importance of evaluating benefit assessments from the viewpoint of various stakeholders, such as patients, physicians and insurers, is rapidly rising. This seminar ̶ led by Gordon Gochenauer, Director, Commercial Planning (U.S.), and Andrew Miniuks, Senior Director, Commercial Planning (Europe) ̶ will cover:
- U.S. and European Healthcare Systems: Do patients have access to the needed treatments and medications?
- Pricing and Reimbursement: Will the drugs be reimbursed by insurance?
- Stakeholder Relationships: How should pharmaceutical companies build relationships with stakeholders?
- Case Studies in Oncology: Recent pricing, reimbursement and coverage decisions that highlight similarities and differences between the U.S. and Europe
The seminar will begin at 1 pm. Visit Synix’s website to register for this event (http://www.synix.co.jp/assessment/seminar/20131114/detail.html) or contact Gen Okamoto for more information.
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.